Abstract 599TiP
Background
Hepatocyte growth factor receptor (HGF)/mesothelial-epithelial transition (MET) pathway activation is known as an oncogenic driver in NSCLC. MET overexpression has been reported to be associated with worse clinical outcomes of NSCLCs. In China, the current second-line standard of care for EGFR/ALK/ROS1/METex14m-wildtype NSCLC with MET overexpression is mono-chemotherapy or immune checkpoint inhibitor, but with limited efficacy. Preclinically, the synergistic effect of savolitinib and docetaxel was tested in both CDX and PDX models. A phase I study explored the safety and tolerability of savolitinb plus docetaxel in advanced solid tumors. This study (NCT05777278) aims to explore the efficacy and safety of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression.
Trial design
This is an ongoing, phase I/II, pilot, open-label, single arm, single center, interventional study. Eligible patients will be those diagnosed with MET overexpression, EGFR/ALK/ROS1/METex14m-wildtype NSCLC in advanced stages and not treated with MET inhibitors. MET overexpression is defined as IHC 3+ in ≥50% of tumor cells. Patients will receive docetaxel (60 mg/m2, ivgtt, q3w) and savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID) after signing informed consent. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, other discontinuation criterion is met, or study completion. The primary objectives include assessing the efficacy by Objective Response Rate (ORR) and the safety and tolerability profile of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression. The secondary objective is to assess the efficacy through Progression-Free Survival (PFS), Duration of Response (DoR), Disease Control Rate (DCR), Overall Survival (OS), 12 months OS rate using investigator assessments according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1). The exploratory objective is to assess efficacy in the MET-high (in 90% tumor cells IHC 3+) population.
Clinical trial identification
NCT05777278, 03/17/2023.
Legal entity responsible for the study
The authors.
Funding
AstraZeneca, China and Hutchison Whampoa, China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract